Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anteris Technologies Global Corp. - Common Stock (NQ:AVR)

4.950 +0.220 (+4.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 360,259
Open 4.700
Bid (Size) 4.930 (100)
Ask (Size) 4.950 (400)
Prev. Close 4.730
Today's Range 4.685 - 5.110
52wk Range 2.340 - 8.790
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Top movers in Thursday's after hours session ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
From Anteris Technologies Global Corp.
Via GlobeNewswire

Performance

YTD
-10.8%
-10.8%
1 Month
+38.7%
+38.7%
3 Month
-14.9%
-14.9%
6 Month
+23.4%
+23.4%
1 Year
-10.0%
-10.0%

More News

Read More
News headline image
Anteris Announces Results for the Third Quarter of 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Top 2 Health Care Stocks That May Keep You Up At Night This Month ↗
Via Benzinga
News headline image
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Announces Results for the Second Quarter of 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Here are the top movers in Tuesday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Anteris Announces Results for the First Quarter of 2025
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Reports 2024 Financial Results and Provides Corporate Update
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays
From Anteris Technologies Global Corp.
Via GlobeNewswire
News headline image
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst ↗
Via Benzinga

Frequently Asked Questions

Is Anteris Technologies Global Corp. - Common Stock publicly traded?
Yes, Anteris Technologies Global Corp. - Common Stock is publicly traded.
What exchange does Anteris Technologies Global Corp. - Common Stock trade on?
Anteris Technologies Global Corp. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Anteris Technologies Global Corp. - Common Stock?
The ticker symbol for Anteris Technologies Global Corp. - Common Stock is AVR on the Nasdaq Stock Market
What is the current price of Anteris Technologies Global Corp. - Common Stock?
The current price of Anteris Technologies Global Corp. - Common Stock is 4.950
When was Anteris Technologies Global Corp. - Common Stock last traded?
The last trade of Anteris Technologies Global Corp. - Common Stock was at 12/16/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.